Patients' attitudes toward detection of heterozygous familial hypercholesterolemia

Archives of Internal Medicine

Volumn 157, Issue 5, 1997, Pages 553-560

  Andersen, Lone K ^a   Jensen, Henrik K ^a   Juul, Svend ^b   Faergeman, Ole ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; AGED; ANXIETY; ARTICLE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; FEAR; FEMALE; HETEROZYGOSITY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PRIORITY JOURNAL; QUESTIONNAIRE; RELATIVE; SCREENING; WELLBEING;

EID: 0031058511     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.5.553     Document Type: Article

References (39)

1. Korenberg JR, Rimoin DL. Medical genetics. JAMA. 1995;273:1692-1693.
2. Gustavson KM. The prevention and management of autosomal recessive conditions: main example: alpha 1-antitrypsIn deficiency. Clin Genet. 1989;36:327-332.
3. Mulvihill JJ. Prospects for cancer control and prevention through genetics. Clin Genet. 1989;36:313-319.
4. Quaid KA. Psychological and ethical considerations in screening for disease. Am J Cardiol. 1993;72:64D-67D.
5. Lerman C, Rimer BK, Engstrom PF. Cancer risk notification: psychosocial and ethical implications. J Clin Oncol. 1991;9:1275-1282.
6. Clarke A. Population screening for genetic susceptibility to disease. BMJ. 1995;311:35-38.
7. Muller Hill B, The shadow of genetic injustice. Nature. 1993,362:491-492.
8. Kessler S, Field T, Worth L, Mosbarger H. Attitudes of persons at risk for Huntington disease toward predictive testing. Am J Med Genet. 1987;26:259-270.
9. Meissen GJ, Berchek RL. Intentions to use predictive testing by those at risk for Huntington's disease: implications for prevention. Am J Community Psy-Chol. 1988;16:261-277.
10. Mastromauro C, Myers RH, Berkman B, Attitudes toward presymptomatic testing in Huntington disease. Am J Med Genet. 1987;26:271-282.
11. Lerman C, Seay J, Balshem A, Audrain J. Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet. 1995;57:385-392.
12. Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol. 1994;12:843-850.
13. Croyle RT, Lerman C, Interest in genetic testing for colon cancer susceptibility: cognitive and emotional correlates. Prev Med. 1993;22:284-292.
14. Meissen GJ, Mastromauro CA, Kiely DK, McNamara DS, Myers RH. Understanding the decision to take the predictive test for Huntington disease. Am J Med Genet. 1991;39:404-410.
15. Brandt J, Quaid KA, Folstein SE, et al. Presymptomatic diagnosis of delayed-onset disease with linked DNA markers: the experience in Huntington's disease. JAMA. 1989;261:3108-3114.
16. Wiggins S, Whyte P, Huggins M, et al. The psychological consequences of predictive testing for Huntington's disease: Canadian Collaborative Study of Predictive Testing. N Engl J Med. 1992;327:1401-1405.
17. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Diseases. 7th ed. New York, NY: McGraw-Hill Inc: 1995:1981-2030.
18. Yamamoto A, Kamiya T, Yamamura T, et al. Clinical features of familial hypercholesterolemia. Arterioscler Thromb Vase Biol. 1989;9:166-174.
19. Jensen J, Blankenhorn DH, Kornerup V. Coronary disease in familial hypercholesterolemia. Circulation. 1967;36:77-82.
20. Koivisto PV, Koivisto UM, Miettinen TA, Kontula K. Diagnosis of heterozygous familial hypercholesterolemia: DNA analysis complements clinical examination and analysis of serum lipid levels. Arterioscler Thromb Vase Biol. 1992;12:584-592.
21. Hobbs HH, Brown MS, Goldstein JL, Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat. 1992;1:445-466.
22. Rudiger NS, Heinsvig EM, Hansen FA, Faergeman O, Bolund L, Gregersen N. DNA deletions in the low density lipoprotein (LDL) receptor gene in Danish families with familial hypercholesterolemia. Clin Genet. 1991;39:451-462.
23. 119-Lys mutation in the low-density lipoprotein receptor gene in two Danish families with heterozygous familial hypercholesterolemia. Hum Mutat. 1994;4:102-113.
24. 66-Gly mutations of the LDL-receptor gene: common causes of familial hypercholesterolemia in Denmark. Atherosclerosis. 1996;120:57-65.
25. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72:171-176.
26. The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994;344:1383-1389.
27. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
28. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
29. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
30. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
31. Illingworth DR, Bacon S. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. Arterioscler Thromb Vasc Biol. 1989;9:1121-1134.
32. Scientific Steering Committee on Behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ. 1991;303:893-896.
33. Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation. 1989;79:225-232.
34. Bild DE, Williams RR, Brewer HB, Herd JA, Pearson TA, Stein E. Identification and management of heterozygous familial hypercholesterolemia: summary and recommendations from an NHLBI workshop. Am J Cardiol. 1993;72:1D-5D.
35. Codori AM, Brandt J. Psychological costs and benefits of predictive testing for Huntington's disease. Am J Med Genet. 1994;54:174-184.
36. Codori AM, Hanson R, Brandt J. Self-selection in predictive testing for Huntington's disease. Am J Med Genet. 1994;54:167-173.
37. Polednak AP, Lane DS, Burg MA, Risk perception, family history, and use of breast cancer screening tests. Cancer Detect Prev. 1991;15:257-263.
38. Kash KM, Holland JC, Halper MS, Miller DG, Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst. 1992;84:24-30.
39. Tonstad S, Noevik TS, Vandvik IH. Psychosocial function during treatment for familial hypercholesterolemia. Pediatrics. 1996;98:249-255.